Johnson & Johnson has been saying for some time that it thinks its combination of Rybrevant and Lazcluze is the best option for patients with EGFR-mutated non-small cell lung cancer (NSCLC) – and now ...
Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial keeps that hope alive. Topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback